Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
Haiti
(0/week)
Guyana
(0/week)
Honduras
(0/week)
Jamaica
(0/week)
Netherlands Antilles
(0/week)
View all
(0/week)
News
United States
(1294/week)
Manufacturing
(577/week)
Energy
(393/week)
Technology
(1132/week)
Other Manufacturing
(401/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
Antengene Corporation Limited
Jul 27, 2025
Antengene Announces Poster Presentation of ATG-022 (Claudin 18.2 ADC) at ESMO 2025
May 20, 2025
Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-022 (CLDN18.2 ADC) In Combination with KEYTRUDA® (pembrolizumab)
Apr 25, 2025
Antengene Presents Four Posters at AACR 2025 Highlighting Focuses on AnTenGagerTM TCEs and Synthetic Lethality
Apr 23, 2025
Antengene to Present Latest Results From Two Clinical Studies at ASCO 2025
Mar 21, 2025
Antengene Announces 2024 Full-Year Financial Results, Proprietary Programs Advancing to Pivotal Trials with Accelerating Multi-market Revenue Ramp Up
Feb 13, 2025
Antengene Announces XPOVIO® Approved for Public Health Insurance Coverage in Taiwan Market, Benefiting More Patients with R/R MM in the Region
Dec 09, 2024
Antengene Presents Results from Two Late-Stage Clinical Studies of Selinexor at ASH 2024
Nov 05, 2024
Antengene Presents Results from Three Investigational Programs at the 2024 SITC Annual Meeting
Nov 05, 2024
Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024
Oct 17, 2024
Antengene Announces XPOVIO® (selinexor) Approved for Its Third Indication in South Korea, Bringing Fresh Hope to Patients with MM in the Country
Oct 04, 2024
Antengene to Present Results from Three Programs at the 2024 SITC Annual Meeting
Sep 23, 2024
Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Thailand
Aug 23, 2024
Antengene Announces 2024 Interim Financial Results, Highlights Progress in R&D and Commercialization
Aug 05, 2024
Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Malaysia
Jun 26, 2024
Antengene Announces XPOVIO® (selinexor) National Health Insurance Service Approval for Reimbursement in South Korea
May 23, 2024
Antengene To Present One Oral and Four Abstracts at ASCO 2024
Apr 25, 2024
Antengene Announces One Oral and Three Poster Presentations at ASCO 2024
Apr 05, 2024
Antengene Presents Four Preclinical Posters at AACR 2024
Apr 05, 2024
Antengene Presents Four Preclinical Posters at AACR 2024
Mar 22, 2024
Antengene Announces Full Year 2023 Financial Results, Highlights Clinical Progress Across First-in-Class, Best-in-Class Pipeline
Page 1
››
Latest News
Aug 18, 2025
AllClear Aerospace & Defense Appoints Bill Boucek as Chief Executive Officer
Aug 18, 2025
Nextracker Releases Fiscal Year 2025 Sustainability Report
Aug 18, 2025
ExxonMobil and Cerebre Sign Long-Term Agreement to Accelerate Foundational Digital Backbone
Aug 18, 2025
Eletrobras Selects C3 AI to Scale Enterprise AI Across Latin America’s Largest Power Utility
Aug 18, 2025
OCOchem and ADM Announce Production Partnership to Build Innovative New CO2 Conversion Facility at ADM...
Aug 18, 2025
Automated Industrial Robotics Inc. Acquires Owens Design
Aug 18, 2025
Forum Energy Technologies Announces Secondary Listing on NYSE Texas
Aug 18, 2025
NRG Energy, Inc. Announces Dual Listing on NYSE Texas
View all News
Agenda
30
September
Portugal
Troia, Portugal
Seabed Security, 30 September - 01 October 2025, Troia, Portugal
Seabed Security | 30 September - 01 October 2025 | Troia, Portugal Defence iQ Announces Inaugural Seabed Security...
23
September
United Kingdom
London, UK
Countering Explosive Threat & Demining conference, September 23 - 24, 2025, London, UK
Countering Explosive Threat & Demining conference | September 23 - 24, 2025 | London, UK The Countering Explosive...
View All Events